Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

Eylea does not have any known drug interactions. However, it’s still important to talk with your doctor about all medications, supplements, and vitamins you use before starting treatment with ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective. The trial was sponsored by the US government-funded ...

Excluding a one-time $40 million inventory charge, Eylea sales would have been in line, he said. "Given significant concerns about the Eylea number we were hearing from many investors going into ...

Listed below are the charts and positions for Eylea HD in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Eylea HD.